Kathryn Jean Boor sold $94k of SRPT
director at Sarepta Therapeutics, Inc.. 761 shares at an average of $122.93, traded Mar 11, 2024, filed Mar 11, 2024.
Score components
- +15RoleDirector
- +10Trade size$94k at market
- 0Share of holdings soldSold 9.2% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.9%, 3m +0.8%, 6m +5.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-029531, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 11, 2024 | SOpen-market sale Common Stock | -761 | $122.93 | $94k | 7,516 | Mar 11, 2024 |
Related signals
Other insiders at Sarepta Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | SRPTsell Sarepta Therapeutics, Inc. | Stephen Mayo director | $123k 7,239 shares | -80% | |
| 34Weak | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Operating Officer | $294k 13,187 shares | -6% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.3M 10,500 shares | -31% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $205k 1,636 shares | -22% | |
| 50Moderate | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Financial Officer | $822k 5,985 shares | -15% | |
| 47Moderate | SRPTbuy Sarepta Therapeutics, Inc. | Michael Andrew Chambers director | $5.0M 37,038 shares | +15% | |
| 23Weak | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $1.9M 11,757 shares | -40% | |
| 33Weak | Sarepta Therapeutics, Inc. | Ryan Edward Brown EVP, General Counsel | $6.3M 38,957 shares | -69% | |
| 18Weak | Sarepta Therapeutics, Inc. | Dallan Murray Chief Customer Officer | $509k 3,635 shares | -17% | |
| 50Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.8M 15,000 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.